Kura Oncology, Inc. (KURA): Shareholders' Equity
$174.13M
As of 2025-12-31
$48.43M
As of 2026-06-30
-25.4%
3-year compound annual growth
-22.2%
5-year compound annual growth
+7.8%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $174.13M | -57.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $413.64M | +4.1% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $397.27M | -5.5% | 2026-03-05, Balance as of period end |
| 2022-12-31 | $420.28M | -17.0% | 2025-02-28, Balance as of period end |
| 2021-12-31 | $506.61M | -17.1% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $610.90M | +179.2% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $218.78M | +35.9% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $160.99M | +101.6% | 2021-02-24, Balance as of period end |
| 2017-12-31 | $79.86M | +40.4% | 2020-02-25, Balance as of period end |
| 2016-12-31 | $56.88M | -30.7% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $82.10M | n/m | 2017-03-14, Balance as of period end |
| 2014-12-31 | -$3.43M | n/m | 2016-03-17, Balance as of period end |
| 2013-12-31 | -$124.0K | n/m | 2015-02-27, Balance as of period end |
| 2012-12-31 | -$95.3K | n/m | 2015-02-27, Balance as of period end |
| 2011-12-31 | -$68.0K | n/m | 2015-02-27, Balance as of period end |
| 2010-12-31 | -$41.0K | n/m | 2015-02-27, Balance as of period end |
| 2009-12-31 | -$18.6K | n/m | 2015-02-27, Balance as of period end |
| 2008-12-31 | $1.4K | -96.0% | 2015-02-27, Balance as of period end |
| 2007-12-31 | $35.0K | n/a | 2015-02-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $36.98M | +13.5% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $64.72M | -49.8% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $722.17M | +7.5% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $206.75M | +519.8% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $305.72M | -34.1% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $609.98M | -23.1% |
Compare KURA, SPRO, RMTI, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗